Introduction
Many patients with acute myeloid leukaemia die before an adequate trial of chemotherapy has been completed. ' The main causes of death are infection and haemorrhage,2 although vascular occlusion with mycloblasts (leukostasis) may cause central nervous,' pulmonary, and cardiac6 effects. Deaths from leukostasis are unusual in patients with blast cell counts less than 100, 109/1 (100 0001mm3),7 and whole-blood viscosity is rarely increased in patients with high counts because of a concomitant reduction in haemoglobin concentration." In the MRC's fourth and fifth leukacmia trials patients with blast counts exceeding 50 10'/1 had a higher mortality in the first six weeks. Generally, deaths from leukostasis would be expected to occur in the first few days of treatment, before a maximal reduction in the blast count.
I describe hcre three patients who prcsented with blast cell counts exceeding 100 109/1 who died from leukostasis shortly after receiving blood transfusions. I also present the results of an analysis of the forms from the fourth and fifth trials to see whether the increased mortality in patients with high blast counts was mainly due to early deaths and whethcr early deaths were related to hyperviscosity produced by a high haemoglobin concentration or blood transfusion. Case 3-A 63-year-old man was admitted with a three-week history of effort dyspnoea and pleuritic pain. He was tachypnoeic but not orthopnoeic. His temperature was 37-9°C, and he had bilateral basal crepitations. There was purpura on his chest, and he had ulcerated gums and tonsils. Peripheral pulses were present. Blood film showed acute myeloblastic leukaemia, with blast count 340 x 109/l, haemoglobin 10-3 g/dl, and platelet count 18 x 109/l. Serum potassium concentration was 2-5 mmol (mEq)/l. The patient was treated with intravenous cephaloridine, frusemide, and intravenous potassium chloride. Blood transfusion of four units was started and chemotherapy with daunorubicin and cytosine arabinoside given. Over the next 24 hours the crepitations improved but he became increasingly dyspnoeic, centrally cyanosed, and confused. Haemoglobin was 13-8 g/dl, blast count 108 x 109/1, and platelet count 10 x 109/1. He complained of numbness in his left leg, and the femoral, popliteal, and dorsalis pedis pulses were indetectable. He became comatose and died. Permission for necropsy was not obtained.
Methods
Results Table I gives the number of patients who died in the first week after diagnosis. Patients with blast counts exceeding 100 x 109/l had a mortality of 25 % compared with 5 % in the group with lower blast BRITISH MEDICAL JOURNAL 6 MAY 1978 counts. Since increasing age and low platelet count are adverse prognostic factors they were compared between the three groups of patients. Table II shows that there was no difference in mean ages but that the mean platelet count in the patients with low blast counts who died within a week was significantly lower than in patients with high blast counts.
The main difference between patients with high blast counts who died early and those who survived was in haemoglobin, the concentration in the survivors being significantly lower (table III) . Blood transfusion was not given more often to patients who died early, since they had a higher haemoglobin concentration. Table III shows that in most of the survivors haemoglobin was less than 10 5 g/dl when the blast count was over 100 S 109/1.
The three patients who survived with high haemoglobin concentrations were all treated on the day of diagnosis. Only one of the 11 patients dying early with a high blast count received chemotherapy on the day of diagnosis, although 10 received chemotherapy. Only half the patients were given chemotherapy within the first two days after diagnosis. Because the initial haemoglobin concentration in the survivors was low, by the time it had risen to at least 10 5 g dl the peripheral blast counts had fallen to below 50 x 101' 1, despite the delay in gving chemotherapy. Table IV gives the main causes of death. Neurological deterioration was the most common cause in both the high and low blast count groups. Necropsy reports were available on three patients who died with high blast counts, one of whom is reported as case 2. A limited report only was available on one, which showed that blood vessels in the lung had 90°'0 of their lumina occupied by blast cells. In the re- maining patient haemoglobin was 13 7 g dl on presentation, blast count 160 X 101',, and platelet count 18 10'1l. He had a cerebral haemorrhage with intravascular leukostasis.
Discussion
A previous necropsy study-of patients dying with high blast cell counts showed that leukaemic thrombi and aggregates were most commonly found in the lungs and, brain and were unusual in patients with blast counts below 100 10!1/l. Often patients became confused and dyspnoeic shortly before death.
Nevertheless, unless postmortem examinations are performed, cerebral haemorrhage due to leukostasis is difficult to distinguish from that due to low platelet counts. The results of the fourth and fifth MRC trials showed that patients with high blast counts have a greatly increased early mortality, which cannot be accounted for by other high-risk factors. In the few patients on whom necropsy was performed leucocyte aggregates were found in the areas seen clinically to be affected. The cause of thesc aggregates is not clear, but the viscosity of whole blood with high blast counts is 75",, greater than expected from the packed cell volume (lPCV).> The viscosity of leukaemic-cell suspensions is only slightly greater than that of red cells of the same PCV. Leukaemic cells are much less deformable than red blood cells," and the pressure required to force nondeformable cells through filters increases with increasing PCV. Most patients with leukaemia and a high blast count have a low haemoglobin concentration on presentation, and thus the actual viscosity is no greater than that of a normal PCV of 0-47 (47",,).
In the patients who died within a week, however, the haemoglobin concentration was significantly higher than in the survivors. Since viscosity is log-linearly related to PCV throughout the range of PCV these patients would have had a higher wholeblood viscosity. Thomas et al l' showed that a small change in PCV in the normal range could produce a 50'°,O change in cerebral blood flow. The combination of a viscosity greater than expected for a given PCV together with rigid blast cells may have led to leukostasis. The three patients described deteriorated rapidly on transfusion to haemoglobin concentrations of at least 10 g/dl, and although necropsy was not carried out in case 3, leukostasis was the most likely explanation of the clinical events.
The platelet count in the reported cases fell over the 24 hours after admission. This was unlikely to have been due to chemotherapy, and there was no bleeding from venepuncture sites or fresh haemorrhage such as may occur with disseminated intravascular coagulation, although blood cultures were positive in one patient. The fall in platelet count could have led to cerebral bleeding, but the postmortem examinations showed leukostasis as described by Freireich et al. 4 Alternatively, the fall could have been produced by haemorrhage associated with leukostasis consuming platelets. In either case it would have predisposed to further bleeding in areas of leukostasis.
As patients with high blast counts whose disease went into remission survived as long as those with lower counts,' it is important to prevent these early deaths. A haemoglobin concentration above 10 g/dl is an adverse risk factor. Transfusing patients to this concentration before their blast count has been reduced should be avoided as it may lead to early death by encouraging leukostasis. The only survivors whose haemoglobin concentration was over 10 g/dl had received chemotherapy on the day of diagnosis. Conventional chemotherapy halved the blast count within 24 hours in most patients and should be started as a matter of urgency.
Introduction
Clofibrate is used extensively for hyperlipidaemia and is effective and palatable. It acts on the liver to enhance the biliary
